An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

Completed · Phase 3

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either: Group 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and dexamethasone OR Group 3: nivolumab, elotuzumab, pomalidomide and dexamethasone. Enrollment is closed for all groups.

Key facts

Study ID

NCT02726581

Run by

Bristol-Myers Squibb

People needed

170

Starts

2016-08-10

Expected to finish

2022-03-09

Last updated by the study team

2023-03-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Refractory or relapsed and refractory multiple myeloma
• Measurable disease
• Have received ≥ 2 lines of prior therapy which must have included an immune modulatory drug (IMiD) and a proteasome inhibitor alone or in combination

You may not qualify if…

• Solitary bone or extramedullary plasmacytoma disease only
• Active plasma cell leukemia
• Other protocol defined inclusion/exclusion criteria apply

Where it is running

• Local Institution - 0160 — Mobile, Alabama, United States
• Local Institution - 0163 — Fayetteville, Arkansas, United States
• Local Institution - 0118 — Bakersfield, California, United States
• Local Institution - 0093 — Corona, California, United States
• Local Institution - 0016 — Fountain Valley, California, United States
• Local Institution - 0164 — La Jolla, California, United States
• UC San Diego Moores Cancer Ctr — La Jolla, California, United States
• Local Institution - 0138 — Los Angeles, California, United States
• Local Institution - 0155 — Los Angeles, California, United States
• Local Institution - 0117 — Redondo Beach, California, United States
• Local Institution - 0092 — Riverside, California, United States
• Coastal Integrative Cancer Care — San Luis Obispo, California, United States
• Local Institution - 0113 — Santa Maria, California, United States
• Colorado Blood Cancer Institute — Denver, Colorado, United States
• Poudre Valley Health Care — Fort Collins, Colorado, United States
• Local Institution - 0116 — Grand Junction, Colorado, United States
• Yale University School Of Medicine — New Haven, Connecticut, United States
• Local Institution - 0147 — Washington D.C., District of Columbia, United States
• Local Institution - 0011 — Boynton Beach, Florida, United States
• Florida Cancer Specialists S. — Fort Myers, Florida, United States
• Local Institution - 0114 — Hollywood, Florida, United States
• Cancer Specialists of North FL — Jacksonville, Florida, United States
• Local Institution - 0082 — Pensacola, Florida, United States
• Local Institution - 0126 — St. Petersburg, Florida, United States
• Local Institution - 0020 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.